Nasal Bacteria Could Predict Skin Infections
By LabMedica International staff writers Posted on 05 Jun 2014 |

Image: Scanning electron micrograph of Methicillin-resistant Staphylococcus aureus and a dead human neutrophil (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Bacteria found in the nose may be a key indicator for future development of skin and soft-tissue infections in remote areas of the body.
The nose is the primary reservoir of Staphylococcus aureus in humans and in nearly 80% of the cases, an individual's colonizing strain is the same strain that causes subsequent remote skin infections. However, until now, no one has been able to determine why some S. aureus carriers develop infections while others do not.
Scientist at the Uniformed Services University of the Health Sciences (Bethesda, MD, USA) postulated that the population of S. aureus in an individual's nose may harbor valuable clues regarding skin and soft tissue infections (SSTI) susceptibility that had not yet been described. This is of particular interest to the military, as it is well known that soldiers in training are at increased risk of developing an SSTI. They collected nasal samples and cultures from 86 infantry soldiers and for those individuals among the 86 who developed SSTIs, the investigators also collected samples and cultures from within the soldiers' skin abscesses.
The team used a high-throughput DNA sequencing strategy to determine the microbial composition of each sample. The biodiversity of the bacterial population in each nose was compared between individuals colonized and/or infected with Methicillin-Resistant S. aureus (MRSA), Methicillin-Sensitive S. aureus (MSSA), and those individuals that were culture-negative for S. aureus.
The scientists observed a significantly higher percentage of a type of bacteria known as Proteobacteria in the noses of individuals who did not develop SSTI, suggesting that Proteobacteria may, in fact, be protective against the development of SSTIs. Furthermore, S. aureus carriers had a unique nasal microbiome that differed from non-carriers. The Proteobacteria are a major phylum of bacteria. They include a wide variety of pathogens, such as Escherichia, Salmonella, Vibrio, Helicobacter, and many other notable genera.
The scientists concluded that by establishing a nose marker microbiome associated with development of SSTI infections may pave the way for focused preventive treatments that target the microbiome, rather than S. aureus itself. They believe that this study will aid in the design of future prophylactic procedures that can help prevent SSTI, particularly in the setting of military training, and help influence how health care providers think about and treat these complex and diverse infections. The study was presented at the 114th General Meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
Uniformed Services University of the Health Sciences
The nose is the primary reservoir of Staphylococcus aureus in humans and in nearly 80% of the cases, an individual's colonizing strain is the same strain that causes subsequent remote skin infections. However, until now, no one has been able to determine why some S. aureus carriers develop infections while others do not.
Scientist at the Uniformed Services University of the Health Sciences (Bethesda, MD, USA) postulated that the population of S. aureus in an individual's nose may harbor valuable clues regarding skin and soft tissue infections (SSTI) susceptibility that had not yet been described. This is of particular interest to the military, as it is well known that soldiers in training are at increased risk of developing an SSTI. They collected nasal samples and cultures from 86 infantry soldiers and for those individuals among the 86 who developed SSTIs, the investigators also collected samples and cultures from within the soldiers' skin abscesses.
The team used a high-throughput DNA sequencing strategy to determine the microbial composition of each sample. The biodiversity of the bacterial population in each nose was compared between individuals colonized and/or infected with Methicillin-Resistant S. aureus (MRSA), Methicillin-Sensitive S. aureus (MSSA), and those individuals that were culture-negative for S. aureus.
The scientists observed a significantly higher percentage of a type of bacteria known as Proteobacteria in the noses of individuals who did not develop SSTI, suggesting that Proteobacteria may, in fact, be protective against the development of SSTIs. Furthermore, S. aureus carriers had a unique nasal microbiome that differed from non-carriers. The Proteobacteria are a major phylum of bacteria. They include a wide variety of pathogens, such as Escherichia, Salmonella, Vibrio, Helicobacter, and many other notable genera.
The scientists concluded that by establishing a nose marker microbiome associated with development of SSTI infections may pave the way for focused preventive treatments that target the microbiome, rather than S. aureus itself. They believe that this study will aid in the design of future prophylactic procedures that can help prevent SSTI, particularly in the setting of military training, and help influence how health care providers think about and treat these complex and diverse infections. The study was presented at the 114th General Meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
Uniformed Services University of the Health Sciences
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more